CN109069448B - 用于治疗肝癌的组合物和方法 - Google Patents

用于治疗肝癌的组合物和方法 Download PDF

Info

Publication number
CN109069448B
CN109069448B CN201780011693.6A CN201780011693A CN109069448B CN 109069448 B CN109069448 B CN 109069448B CN 201780011693 A CN201780011693 A CN 201780011693A CN 109069448 B CN109069448 B CN 109069448B
Authority
CN
China
Prior art keywords
substituted
hydrogen
certain embodiments
heteroaryl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780011693.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN109069448A (zh
Inventor
刘胜勇
陈志铭
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Golden Biotechnology Corp
Original Assignee
Golden Biotechnology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Golden Biotechnology Corp filed Critical Golden Biotechnology Corp
Publication of CN109069448A publication Critical patent/CN109069448A/zh
Application granted granted Critical
Publication of CN109069448B publication Critical patent/CN109069448B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/22—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/527—Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings
    • C07C49/543—Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings to a six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/527—Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings
    • C07C49/557—Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings having unsaturation outside the rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201780011693.6A 2016-02-17 2017-02-16 用于治疗肝癌的组合物和方法 Active CN109069448B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662296097P 2016-02-17 2016-02-17
US62/296,097 2016-02-17
PCT/US2017/018236 WO2017143106A1 (en) 2016-02-17 2017-02-16 Compositions and methods for treating liver cancer

Publications (2)

Publication Number Publication Date
CN109069448A CN109069448A (zh) 2018-12-21
CN109069448B true CN109069448B (zh) 2021-09-21

Family

ID=59625477

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780011693.6A Active CN109069448B (zh) 2016-02-17 2017-02-16 用于治疗肝癌的组合物和方法

Country Status (9)

Country Link
US (1) US10858307B2 (enExample)
EP (1) EP3416630B1 (enExample)
JP (1) JP6932342B2 (enExample)
KR (1) KR102399856B1 (enExample)
CN (1) CN109069448B (enExample)
AU (1) AU2017219871B2 (enExample)
ES (1) ES2961932T3 (enExample)
TW (1) TWI737683B (enExample)
WO (1) WO2017143106A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025165622A1 (en) * 2024-01-31 2025-08-07 Golden Biotechnology Corporation Therapeutic compositions for treating liver cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI394573B (zh) * 2007-06-14 2013-05-01 國鼎生物科技股份有限公司 Application of Cynanchum auranthone Cyclohexenone Compounds in the Preparation of Drugs for Liver Protection
CN101417934B (zh) * 2007-10-24 2012-04-18 国鼎生物科技股份有限公司 分离自牛樟芝萃取物的化合物
FR2987264A1 (fr) * 2012-02-23 2013-08-30 Golden Biotechnology Corp Methodes et compositions pour le traitement des metastases cancereuses
TWI597061B (zh) * 2013-02-20 2017-09-01 國鼎生物科技股份有限公司 治療白血病之方法及組成物
TWI612026B (zh) * 2013-02-20 2018-01-21 國鼎生物科技股份有限公司 環己烯酮組成物及其製造方法

Also Published As

Publication number Publication date
JP2019507133A (ja) 2019-03-14
US20190112258A1 (en) 2019-04-18
EP3416630B1 (en) 2023-10-25
KR20180118634A (ko) 2018-10-31
CA3014057A1 (en) 2017-08-24
US10858307B2 (en) 2020-12-08
AU2017219871A1 (en) 2018-08-16
WO2017143106A1 (en) 2017-08-24
TWI737683B (zh) 2021-09-01
ES2961932T3 (es) 2024-03-14
EP3416630A4 (en) 2019-10-09
AU2017219871B2 (en) 2020-09-03
KR102399856B1 (ko) 2022-05-20
EP3416630A1 (en) 2018-12-26
TW201733976A (zh) 2017-10-01
EP3416630C0 (en) 2023-10-25
CN109069448A (zh) 2018-12-21
JP6932342B2 (ja) 2021-09-08

Similar Documents

Publication Publication Date Title
CA2990696C (en) (r)- and (s)-1-(3-(3-n,n-dimethylaminocarbonyl)phenoxyl-4-nitrophenyl)-1-ethyl-n,n'-bis (ethylene)phosphoramidate, compositions and methods for their use and preparation
CN109867675B (zh) 一种吡咯并嘧啶衍生的化合物、药物组合物以及其用途
JP7689690B2 (ja) ヒドロキシ安息香酸誘導体、その方法および使用
CN112174940A (zh) 3-(6,7-双(2-甲氧乙氧基)-喹唑啉-4-胺基)苯基-1h-三氮唑衍生物
Miao et al. Novel hybrid CHC from β-carboline and N-Hydroxyacrylamide overcomes drug-resistant hepatocellular carcinoma by promoting apoptosis, DNA damage, and cell cycle arrest
CN104603133B (zh) 用于治疗癌症和免疫抑制的组合疗法
US10561681B2 (en) Antimetastatic 2H-selenopheno[3,2-h]chromenes, synthesis thereof, and methods of using same agents
Sidoryk et al. An efficient synthesis of indolo [2, 3-b] quinoline guanidine derivatives with their in vitro and in vivo study
EP3950677A1 (en) Quinolyl-containing compound and pharmaceutical composition, and use thereof
CN109069448B (zh) 用于治疗肝癌的组合物和方法
EP3773544B1 (en) Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy
HK40000360A (en) Compositions and methods for treating liver cancer
US9175001B2 (en) [1,3] dioxolo [4,5-g] [1,2,4] triazolo [1,5-a] quinoline derivatives as inhibitors of the late SV40 factor (LSF) for use in treating cancer
CN116478147A (zh) 抑制rna解旋酶dhx33活性的氘代化合物、合成方法、药物组合物及用途
EP3560914A1 (en) Sulfonyl amidine as indoleamine-2,3-dioxygenase inhibitor, and preparation method therefor and use thereof
CN111848572A (zh) 酰胺类化合物及其制备方法和用途
CN113861214A (zh) 1,2,3-三唑栓系双氢青蒿素-靛红杂化物及其制备方法和应用
CN107417672A (zh) 一种基于2,2‑二甲基‑3‑（2‑硝基咪唑基）丙酸的低氧激活前药
CN107011266B (zh) 苯并吲唑类衍生物的前药及其制备方法、应用
CA3014057C (en) Compositions and methods for treating liver cancer
TWI569800B (zh) 吉西他濱（Ｇｅｍｃｉｔａｂｉｎｅ）衍生物，其製法及其做為前驅藥物之用途
HK40043232B (zh) 磷脂-flavagline缀合物及将其用於靶向癌症治疗的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40000360

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 40000360

Country of ref document: HK